Employer GLP 1 coverage for weight loss stalls at 18 percent in KFF survey

Employer GLP 1 coverage for weight loss has stalled in the United States, the 2026 KFF Employer Health Benefits Survey shows. Among firms with 200 or more workers that offer health benefits, 18% cover GLP 1 drugs for weight loss in their largest plan, against 19% last year and two years ago. KFF published the survey on October 22. It also found more firms attaching conditions to coverage, and 12% of firms that do not cover the drugs said they had stopped within the past year.

What the KFF survey found

The survey is the 28th annual edition of KFF's study of job based health insurance. Its GLP 1 questions cover drugs such as semaglutide and tirzepatide when used for weight loss, not for diabetes, which plans generally treat as a separate benefit. Coverage rises with firm size, according to the KFF survey report. It stands at 16% of firms with 200 to 999 workers, 29% of firms with 1,000 to 4,999 workers and 33% of firms with 5,000 or more. Large employers are therefore still far more likely to pay for these drugs than mid sized ones. The flat overall share is the key result. After two years of intense demand for obesity drugs, the proportion of larger firms willing to cover them has not grown.

The same survey asked firms that do not cover the drugs about their plans. Only 1% said they were very likely to add coverage within the next 12 months, and 13% said somewhat likely. Most, 79%, said they were not likely to start. A further 12% of the non covering firms said they had stopped covering GLP 1 drugs for weight loss during the past 12 months, which points to some movement out of coverage even while the total stays level. KFF's report does not name the employers involved or give their reasons. Its figures describe the largest health plan at each firm, so workers in other plans at the same company may face different rules.

Conditions attached to GLP 1 coverage

Where employers do pay, they increasingly set conditions. Among covering firms, 40% require enrollees to meet with a dietitian, case manager or therapist, or to join a lifestyle program, before or while receiving the drugs, up from 34% last year. The share reaches 59% among firms with 5,000 or more workers. The survey summary does not say how many of these plans also use prior authorisation or body mass index limits. For patients, conditions of this kind mean that coverage on paper may still require extra appointments and paperwork. The trend fits what benefits advisers have described this year as a move from simple coverage to managed programs.

Among covering firms, 40% require enrollees to meet with a dietitian, case manager or therapist, or to join a lifestyle program, before or while receiving the drugs, up from 34% last year.

Cost is the main pressure behind the conditions. Among covering firms, 29% told KFF that the drugs had a significant effect on their prescription drug spending, 27% a moderate effect, 23% a minor effect and 10% no effect, while 11% did not know. The share reporting a significant effect climbs with size, from 21% of firms with 200 to 999 workers to 61% of firms with 5,000 or more. Those are the employers most likely to cover the drugs in the first place. The survey also puts the average annual family premium at $28,303 in 2026, up 5% from last year, which frames the budgets inside which benefit teams weigh GLP 1 coverage against other costs.

Other employer surveys point the same way

A separate survey from the Business Group on Health, which represents large employers, pointed in the same direction earlier this year. SHRM reported in May that among the 105 employers surveyed, 67% covered GLP 1 drugs for weight management. Of those covering, 72% said they would likely continue in 2027 and 10% said they likely would not, according to the SHRM report. The group's members are mostly very large companies, so its coverage share runs higher than the KFF figure for all firms with 200 or more workers. The two surveys use different samples and questions. They should not be combined into one number, but both describe employers that are holding coverage steady or trimming it rather than expanding it.

Employers in the Business Group on Health survey gave reasons that match the KFF cost data. Ellen Kelsay, the group's president and chief executive, told SHRM that "companies cannot ignore the reality that GLP-1s have significant implications for healthcare budgets." More than half of covering employers expected clear clinical benefits, SHRM reported, but few had yet seen them in their own claims, such as lower obesity rates or fewer bariatric operations. Most respondents, 87%, expected oral GLP 1 drugs to raise demand, and 9% expected prices to fall. Those answers point to a central doubt for benefit managers. They pay now for a drug whose savings, if they come, may arrive years later.

What comes next for employer coverage

The arrival of oral drugs is the next test. The FDA approved a tablet form of Wegovy in late 2025, as covered in our report on the first GLP 1 pill for weight management, and Lilly's oral drug Foundayo followed in April 2026. Employers in the Business Group survey expected the pills to draw new users who avoided weekly injections, which would raise total spending even if prices per prescription fall. Prices, rebates and direct to employer contracts with drugmakers are all moving. None of the surveys can yet show how those deals will change coverage decisions for 2027. Our industry desk follows pricing and coverage of peptide drugs as plans for next year are published.

For workers, the practical result is a patchwork. Coverage depends on the size of the employer, the plan chosen and the conditions attached, and it can change at each annual enrollment. KFF's figures show that most larger firms still do not cover GLP 1 drugs for weight loss, and that those that do are adding steps such as lifestyle programs. People who rely on these medicines can check their plan documents for the coming year, ask their benefits office about any new requirements and discuss options with their prescriber. The surveys describe employer plans only. They do not cover Medicare, Medicaid or individual market plans, which follow different rules.

Conclusion

GLP 1 coverage for weight loss has stopped growing among larger US employers, with KFF putting the share at 18% in 2026. More covering firms now require lifestyle programs or counselling, and many report a significant hit to drug spending. A separate employer survey points to some plans dropping the drugs in 2027. Workers should check next year's plan terms before enrollment closes.